NCT05691465 2026-03-18
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
34 trialsNCT00001160 2026-03-11
Studies on Tumors of the Thyroid
National Institutes of Health Clinical Center (CC)
Recruiting
NCT06379217 2026-03-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
NCT06427798 2026-03-10
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT04298541 2026-02-27
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Weill Medical College of Cornell University
Phase 2 Not yet recruiting
NCT04074135 2026-02-24
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03206060 2026-02-17
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04040088 2026-01-08
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
Mayo Clinic
Phase EARLY_PHASE1 Active not recruiting
NCT07150806 2025-12-22
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07284589 2025-12-16
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
Nuclear Imaging Institute
Phase 2 Recruiting
NCT04082520 2025-12-11
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
Phase 2 Recruiting
NCT06479811 2025-11-25
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04609592 2025-09-09
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Phase 1 Recruiting
NCT01879657 2025-08-06
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
Radio Isotope Therapy of America
Phase NA Completed
NCT06455358 2025-05-30
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
University Hospital, Basel, Switzerland
Phase 1/2 Recruiting
NCT03602911 2025-03-12
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
West Virginia University
Phase 2 Completed
NCT06520319 2024-07-25
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
First Affiliated Hospital of Fujian Medical University
Phase 1 Recruiting
NCT01873248 2024-07-19
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT05069220 2024-03-01
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT05990998 2024-02-26
A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Completed
NCT03623984 2023-09-11
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
University of Alabama at Birmingham
Phase EARLY_PHASE1 Withdrawn
NCT00001277 2022-06-07
Studies of Elevated Parathyroid Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01869725 2021-09-22
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Phase 2 Completed
NCT03125629 2021-04-09
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
Stanford University
Phase 2 Completed
NCT03001349 2021-02-15
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT04689893 2021-01-05
Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO
Peking Union Medical College Hospital
Phase 1 Unknown
NCT03197012 2020-07-07
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
University of California, San Francisco
Phase EARLY_PHASE1 Completed
NCT01967537 2019-11-19
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT04041882 2019-08-01
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown
NCT03057509 2019-06-21
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Massachusetts General Hospital
Phase 1 Withdrawn
NCT01980732 2017-08-23
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Stanford University
No longer available
NCT02194452 2017-04-28
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
University of Iowa
Phase NA Withdrawn
NCT01524016 2017-04-07
68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown